... final approval for the Company's Abbreviated New Drug Application for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg. ...
... has granted final approval for its Abbreviated New Drug Application for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg. ...
... final approval for the Company's Abbreviated New Drug Application for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg. ...
... final approval for the Company's Abbreviated New Drug Application for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg. ...
... has granted final approval for its Abbreviated New Drug Application for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg. ...
all 13 news articles
... news | PowerRating) who alleged it had infringed its patent on extended release metformin hydrochloride tablets for the treatment of diabetes type II. ...
By Staff Writer Glumetza (metformin hydrochloride extended release tablets) is indicated alone or in combination with a sulfonylurea or insulin as an ...
... from the US Food and Drug Administration (FDA) for the 1000 mg strength tablets of GlumetzaTM (metformin hydrochloride extended release tablets). ...
... from the US Food and Drug Administration (FDA) for the 1000 mg strength tablets of GlumetzaTM (metformin hydrochloride extended release tablets). ...